The global urolithiasis management devices market size was estimated to be USD 13.22 billion in 2023 and is expected to reach USD 22.66 billion by 2034 with a CAGR of 5.02% during the forecast period 2024-2034. The rising prevalence of urolithiasis, the growing geriatric population, rising awareness of minimally invasive surgeries, advancements in technology, and government initiatives are some key factors that will drive the market growth.
Technological developments in medical treatment, such as robotic-assisted surgeries, laser lithotripsy, and less invasive procedures, have been driving the market for urolithiasis management devices. Solutions for less intrusive treatment are becoming more and more popular with patients and medical professionals. For instance, Olympus Corporation introduced the cutting-edge "CHIEFTM Ureteroscope System" in February 2023, which offers enhanced visibility and agility for intracorporeal treatments.
By treatment type, the intracorporeal lithotripsy segment accounted for the highest revenue-grossing segment in the global urolithiasis management devices market in 2023 owing to the developments in minimally invasive surgery and the rising incidence of kidney stones globally. As intracorporeal lithotripsy devices provide accurate and effective stone fragmentation within the urinary tract along with fewer post-operative problems and faster recovery times, their demand has exploded. For instance, Boston Scientific Corporation made a strategic investment in Acotec Scientific Holdings Limited in December 2022. Through this investment, they will be able to offer more vascular closure devices in the future, which may affect the development of new urological products. Additionally, the extracorporeal shock wave lithotripsy (ESWL) segment is predicted to grow at the fastest CAGR during the forecast period owing to the Increasing prevalence of kidney stones, growing preference for non-invasive therapies, and developments in ESWL technologies. As extracorporeal shock wave lithotripsy is non-invasive, requires less recovery time, and has a lower risk of problems than invasive procedures, its demand is anticipated to expand rapidly.
By product type, the lithotripters segment accounted for the highest revenue-grossing segment in the global urolithiasis management devices market in 2023 owing to the increased prevalence of kidney stones, growing awareness among healthcare professionals and patients, and advancements in lithotripter technologies. For instance, the "LLenovoTM iSpyTM XL Flexible Ureteroscope" was introduced by Stryker Corporation in January 2024 and features greater viewing capabilities for better stone targeting. Additionally, the flexible ureteroscopes segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing demand for less invasive procedures, rising cases of complex kidney stones, and continuous improvements in flexible ureteroscope design and imaging technologies.
By End-User, the hospitals & clinics segment accounted for the highest revenue-grossing segment in the global urolithiasis management devices market in 2023 owing to the increased patient admissions for urolithiasis treatment, the availability of advanced medical infrastructure in established healthcare facilities, and a growing number of surgical interventions. For instance, Richard Wolf GmbH introduced the "Kobra Prime Flexible Ureteroscope" in October 2023, which has superior deflection and working channels for better surgical access. Additionally, the ambulatory surgical centers segment is expected to grow at the fastest CAGR during the forecast period, owing to an increase in outpatient procedures, a focus on cost-effective healthcare solutions, and advancements in minimally invasive urolithiasis management technologies.
North American region is anticipated to have the highest revenue share during the forecast period owing to the well-established healthcare infrastructure, a high prevalence of urolithiasis cases, and increasing adoption of advanced urolithiasis management devices. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing awareness of urolithiasis, a growing geriatric population, and expanding healthcare infrastructure. For instance, EDAP TMS S.A. received FDA permission in November 2023 for their focused ultrasound technique for kidney stone treatment called "Sonolith i-Pulse."
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Technological developments in medical treatment, such as robotic-assisted surgeries, laser lithotripsy, and less invasive procedures, have been driving the market for urolithiasis management devices. Solutions for less intrusive treatment are becoming more and more popular with patients and medical professionals. For instance, Olympus Corporation introduced the cutting-edge "CHIEFTM Ureteroscope System" in February 2023, which offers enhanced visibility and agility for intracorporeal treatments.
By treatment type, the intracorporeal lithotripsy segment accounted for the highest revenue-grossing segment in the global urolithiasis management devices market in 2023 owing to the developments in minimally invasive surgery and the rising incidence of kidney stones globally. As intracorporeal lithotripsy devices provide accurate and effective stone fragmentation within the urinary tract along with fewer post-operative problems and faster recovery times, their demand has exploded. For instance, Boston Scientific Corporation made a strategic investment in Acotec Scientific Holdings Limited in December 2022. Through this investment, they will be able to offer more vascular closure devices in the future, which may affect the development of new urological products. Additionally, the extracorporeal shock wave lithotripsy (ESWL) segment is predicted to grow at the fastest CAGR during the forecast period owing to the Increasing prevalence of kidney stones, growing preference for non-invasive therapies, and developments in ESWL technologies. As extracorporeal shock wave lithotripsy is non-invasive, requires less recovery time, and has a lower risk of problems than invasive procedures, its demand is anticipated to expand rapidly.
By product type, the lithotripters segment accounted for the highest revenue-grossing segment in the global urolithiasis management devices market in 2023 owing to the increased prevalence of kidney stones, growing awareness among healthcare professionals and patients, and advancements in lithotripter technologies. For instance, the "LLenovoTM iSpyTM XL Flexible Ureteroscope" was introduced by Stryker Corporation in January 2024 and features greater viewing capabilities for better stone targeting. Additionally, the flexible ureteroscopes segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing demand for less invasive procedures, rising cases of complex kidney stones, and continuous improvements in flexible ureteroscope design and imaging technologies.
By End-User, the hospitals & clinics segment accounted for the highest revenue-grossing segment in the global urolithiasis management devices market in 2023 owing to the increased patient admissions for urolithiasis treatment, the availability of advanced medical infrastructure in established healthcare facilities, and a growing number of surgical interventions. For instance, Richard Wolf GmbH introduced the "Kobra Prime Flexible Ureteroscope" in October 2023, which has superior deflection and working channels for better surgical access. Additionally, the ambulatory surgical centers segment is expected to grow at the fastest CAGR during the forecast period, owing to an increase in outpatient procedures, a focus on cost-effective healthcare solutions, and advancements in minimally invasive urolithiasis management technologies.
North American region is anticipated to have the highest revenue share during the forecast period owing to the well-established healthcare infrastructure, a high prevalence of urolithiasis cases, and increasing adoption of advanced urolithiasis management devices. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing awareness of urolithiasis, a growing geriatric population, and expanding healthcare infrastructure. For instance, EDAP TMS S.A. received FDA permission in November 2023 for their focused ultrasound technique for kidney stone treatment called "Sonolith i-Pulse."
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
Study Coverage
- Market Forecast by Treatment Type, Product Type, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement.
Segmentation: Urolithiasis Management Devices Market Report 2023 - 2034
Urolithiasis Management Devices Market Analysis & Forecast by Treatment Type 2023 - 2034 (Revenue USD Bn)
- Extracorporeal Shock Wave Lithotripsy (ESWL)
- Intracorporeal Lithotripsy
- Percutaneous Nephrolithotomy
- Other
Urolithiasis Management Devices Market Analysis & Forecast by Product Type 2023 - 2034 (Revenue USD Bn)
- Lithotripters
- Intracorporeal
- Extracorporeal
- Ureteroscopes
- Semi-rigid
- Flexible
Urolithiasis Management Devices Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Bn)
- Hospitals and Clinics
- Ambulatory Surgical Centers
- Others
Urolithiasis Management Devices Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Urolithiasis Management Devices Market: Treatment Type Estimates & Trend Analysis
8. Urolithiasis Management Devices Market: Product Type Estimates & Trend Analysis
9. Urolithiasis Management Devices Market: End-User Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Urolithiasis Management Devices Market
12. Europe Urolithiasis Management Devices Market
13. Asia Pacific Urolithiasis Management Devices Market
14. Latin America Urolithiasis Management Devices Market
15. MEA Urolithiasis Management Devices Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Boston Scientific Corporation
- Cook Medical Inc.
- Olympus Corporation
- Siemens Healthineers
- Stryker Corporation
- Dornier MedTech GmbH
- Richard Wolf GmbH
- KARL STORZ SE & Co. KG
- Coloplast Group
- EDAP TMS S.A.
- Lumenis Ltd.
- DirexGroup
- Allengers Medical Systems Ltd.
- Medispec Ltd.
- EMS Electro Medical Systems S.A.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | March 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 13.22 Billion |
| Forecasted Market Value ( USD | $ 22.66 Billion |
| Compound Annual Growth Rate | 5.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
